Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afiveg
- Development stage
- Unknown
- Lead developer
- STADA
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
Afiveg is a biosimilar biological medicine developed by STADA Arzneimittel AG, containing the active substance aflibercept. It is a recombinant fusion protein that functions as a soluble decoy receptor, binding to and neutralizing vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF). By inhibiting these growth factors, Afiveg prevents the abnormal proliferation of blood vessels and reduces vascular leakage in the eye, which are key drivers of several retinal diseases. The drug is indicated for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular edema secondary to retinal vein occlusion (RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV). It is administered via intravitreal injection and was granted marketing authorization in the European Union in August 2025.
- Brand names
- Afiveg
- Other names
- aflibercept
02
Targets
VEGFB (Vascular endothelial growth factor B)PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on afiveg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afiveg.